TMCnet News
AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid TumorsThis novel ADC is expected to have a wider therapeutic index and superior clinical profile across a broad range of solid tumors IND submission is planned for mid-2023 REDWOOD CITY, Calif. and SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, and Evopoint Biosciences Co., Ltd (“Evopoint”), a leading biopharmaceutical company applying its cutting-edge platform technologies to discover and develop innovative medicines, today announced that AmMax has entered into an exclusive option with Evopoint for a worldwide license, excluding Greater China, for the development and commercialization of a novel ADC for treating solid tumors. With its proprietary linker-payload system and monoclonal antibody, this technology has demonstrated robust antitumor activity in multiple preclinical models which presents significant opportunities to treat many different types of cancer. The animal efficacy and toxicity studies also support a significantly widened therapeutic index (TI) that is expected to provide a much-improved efficacy and safety profile. “AmMax’s mission is to develop and commercialize oncology therapeutics that have the potential to become the new standard of care,” said Larry Hsu, Ph.D., Chairman & Chief Executive Officer of AmMax, “Today’s agreement with Evopoint underscores this commitment by adding a potentially best-in-class ADC program to our portfolio. We are excited to partner with Evopoint and, upon exercising the option, to move this highly diffrentiated drug candidate into patient studies in the second half of 2023.” “We are very pleased to enter into this agreement with AmMax,” said Jason Meijie Le, Chief Executive Officer of Evopoint Biosciences. “Evopoint is dedicated to develop and deliver innovative medicines to physicians and patients. We are very impressed with AmMax’s therapeutic area expertise and proven track record in drug development and commercialization. We look forward to partnering with AmMax to advance this transformative product worldwide. This collaboration evidences the superiority of our product pipeline.” Under the exclusive option agreement, the parties have pre-negotiated licensing terms and will work together to complete the upcoming IND filing and design subsequent dose-escalating clinical studies. About AmMax Bio Inc. About Evopoint Contact AmMax Bio, Inc. Evopoint Biosciences Co., Ltd |